Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Suspended 2Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 191Magnetic Resonance Spectroscopy 141Biopsy 102pembrolizumab 82Carboplatin 76Cisplatin 68Nivolumab 62Radiotherapy 51Paclitaxel 51Gemcitabine 50Cyclophosphamide 48Dexamethasone 46durvalumab 39Radiation 39atezolizumab 36Pemetrexed 36olaparib 34Rituximab 34venetoclax 33Etoposide 33Doxorubicin 32Lenalidomide 31X-Rays 30Prednisone 30Bevacizumab 30Docetaxel 28Disulfides 28Immunoglobulin G 27Vincristine 26Ipilimumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × (225)Ac-DOTA-c(RGDyK) × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡